IgAN
12
4
4
1
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
33.3%
4 terminated out of 12 trials
20.0%
-66.5% vs benchmark
25%
3 trials in Phase 3/4
300%
3 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (12)
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
Safety and Efficacy Study of VIS649 for IgA Nephropathy
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
FXS6837 for the Treatment of IgAN Patients
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Efficacy and Safety Study of HS-10542 for IgA Nephropathy
Atacicept in Multiple Glomerular Diseases
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment